French Multicentre Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management Study
FRENCH CORONA
1 other identifier
observational
1,003
1 country
1
Brief Summary
Since December 2019, a new agent, the SARS-Cov-2 coronavirus has been rapidly spreading from China to other countries causing an international outbreak of respiratory illnesses named COVID-19. In France, the first cases have been reported at the end of January with more than 60000 cases reported since then. A significant proportion (20-30%) of hospitalized COVID-19 patients will be admitted to intensive care unit. However, few data are available for this special population in France. We conduct a large observational cohort of ICU suspected or proven COVID-19 patients that will enable to describe the initial management of COVID 19 patients admitted to ICU and to identify factors correlated to clinical outcome.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 3, 2020
CompletedFirst Submitted
Initial submission to the registry
April 7, 2020
CompletedFirst Posted
Study publicly available on registry
April 9, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 3, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
July 3, 2020
CompletedDecember 3, 2025
December 1, 2020
3 months
April 7, 2020
November 25, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Mortality at day 28
Mortality at day 28
day 28
Secondary Outcomes (9)
severe complications
up to day 28
Imaging
day 1
Delay in Microbiological diagnosis
day 1
Antiviral therapy
up to day 28
Antibiotic therapy
day 28
- +4 more secondary outcomes
Study Arms (2)
Suspected or proven COVID-19 critically ill patients
Control
Interventions
Eligibility Criteria
The target population of the study is all patients with suspected or proven SARS-Cov-2 infection (COVID-19)
You may qualify if:
- Patients admitted to ICU for suspected or proven SARS-Cov-2 infection, defined by positive SARS-Cov-2 PCR or CT scan images
- Patient \> or= 18 years
You may not qualify if:
- Patient study refusal
- Patient already enrolled in the present study
- Patient with respiratory illness with negative COVID-19 CT scan images and negative COVID\_19 PCR
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CHU Nimes
Nîmes, 30029, France
Related Publications (1)
Roger C, Collange O, Mezzarobba M, Abou-Arab O, Teule L, Garnier M, Hoffmann C, Muller L, Lefrant JY, Guinot PG, Novy E, Abraham P, Clavier T, Bourenne J, Besch G, Favier L, Fiani M, Ouattara A, Joannes-Boyau O, Fischer MO, Leone M, Ait Tamlihat Y, Pottecher J, Cordier PY, Aussant P, Moussa MD, Hautin E, Bouex M, Julia JM, Cady J, Danguy Des Deserts M, Mayeur N, Mura T, Allaouchiche B; AZUREA group. French multicentre observational study on SARS-CoV-2 infections intensive care initial management: the FRENCH CORONA study. Anaesth Crit Care Pain Med. 2021 Aug;40(4):100931. doi: 10.1016/j.accpm.2021.100931. Epub 2021 Jul 10.
PMID: 34256165RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
CLAIRE ROGER
Centre Hospitalier Universitaire de Nīmes
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 28 Days
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 7, 2020
First Posted
April 9, 2020
Study Start
April 3, 2020
Primary Completion
July 3, 2020
Study Completion
July 3, 2020
Last Updated
December 3, 2025
Record last verified: 2020-12
Data Sharing
- IPD Sharing
- Will not share